14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SRTM vs NIVF: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, SRTM (SRTM) captures the overall head-to-head institutional edge over NewGenIvf Group Limited Class A (NIVF) on higher Unified Composite conviction (47.6/100 HOLD vs. 47.7/100 HOLD) after splitting the core matrix 2–5 (led by Options & Positioning), while NIVF wins 3–1 across the 6-pillar growth and valuation breakdown. SRTM trades at $0.08 (N/M Forward P/E, N/A operating margin) versus NIVF at $0.03 (N/M Forward P/E, -238.2% operating margin).
Growth vs. Quality Trade-Off: SRTM earns the overall head-to-head edge with a stronger Unified Composite Score (47.6/100 HOLD vs. NIVF 47.7/100 HOLD) and N/A risk profile, whereas NIVF leads top-line expansion (-4.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: SRTM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRTM vs NIVF. Trailing 12-month operating profitability (SRTM N/A vs NIVF -238.2%) and valuation multiples (SRTM N/M vs NIVF N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Care Facilities value chain with $98,000 market capitalization and -238.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SRTM vs NIVF Key Questions & Quantitative Answers
As of Nov 20, 2026, SRTM (SRTM) captures the overall head-to-head institutional edge over NewGenIvf Group Limited Class A (NIVF) on higher Unified Composite conviction (47.6/100 HOLD vs. 47.7/100 HOLD) after splitting the core matrix 2–5 (led by Options & Positioning), while NIVF wins 3–1 across the 6-pillar growth and valuation breakdown. SRTM trades at $0.08 (N/M Forward P/E, N/A operating margin) versus NIVF at $0.03 (N/M Forward P/E, -238.2% operating margin). Growth vs. Quality Trade-Off: SRTM earns the overall head-to-head edge with a stronger Unified Composite Score (47.6/100 HOLD vs. NIVF 47.7/100 HOLD) and N/A risk profile, whereas NIVF leads top-line expansion (-4.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SRTM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NIVF leads the Growth & Scale pillar: SRTM posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with NIVF at -4.7% YoY revenue growth and +0.0% YoY earnings growth on $4.6M TTM revenue (23.9% gross margin, -238.2% operating margin). On trailing 12-month operating scale, SRTM generates N/A in USD-normalized revenue versus $4.6M for NIVF. In operating R&D and SG&A reinvestment, SRTM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NIVF.
SRTM and NIVF trade at balanced relative valuation multiples. SRTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NIVF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRTM (N/A ROE) versus NIVF (5.5% ROE) capital efficiency.
In options market volatility and institutional positioning, SRTM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, NIVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.05β · 3040% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.